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Abstract
 Background—Statins may promote vasodilation following subarachnoid hemorrhage (SAH) 
and improve the response to blood pressure elevation. We sought to determine whether simvastatin 
increases cerebral blood flow (CBF) and alters the response to induced hypertension after SAH.
 Methods—Statin-naïve patients admitted <72 hours after WFNS ≥2 aneurysmal SAH were 
randomly assigned to 80 mg simvastatin/day or placebo for 21 days. Regional cerebral blood flow 
(CBF) was measured with quantitative 15O PET on SAH day 7–10 before and after raising mean 
arterial pressure (MAP) 20–25%. Autoregulatory index (AI) was calculated as the ratio of % 
change in resistance (MAP/CBF) to % change in MAP. Angiography was performed within 24 
hours of PET. Results are presented as simvastatin vs. placebo.
 Results—Thirteen patients received simvastatin and 12 placebo. Clinical characteristics were 
similar. Moderate or severe angiographic vasospasm occurred in 42% vs.45% and delayed cerebral 
ischemia in 14% vs. 55% (p=0.074). During PET studies MAP (110±10 vs. 111±12), global CBF 
(41±12 vs. 43±13) and CVR (2.95±1.0 vs. 2.81±1.0) did not differ at baseline. When MAP was 
raised to 135±7 mm Hg vs. 137±15, global CBF did not change. Global AI did not differ 
(107±59 % vs 0. 89±52 %, p=0.68). CBF did not change in regions with low baseline flow or in 
regions supplied by vessels with angiographic vasospasm in either group. Six month modified 
Rankin Scale scores did not differ.
 Conclusions—Our data indicate that initiation of therapy with high-dose simvastatin does not 
alter baseline CBF or response to induced hypertension.
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 Introduction
The rupture of an intracranial aneurysm is a devastating cerebrovascular event that results in 
both acute and delayed cerebral injury. The sudden egress of blood at arterial pressure into 
the subarachnoid space produces a sudden dramatic rise in intracranial pressure, transient 
circulatory arrest and initiates a cascade of events that may culminate in delayed cerebral 
ischemia (DCI). Delayed ischemia, engendering neurological deficits and cerebral 
infarction, is related to critical reductions in cerebral blood flow (CBF) and is a leading 
cause of morbidity in those that survive the initial hemorrhage[1]. DCI may be potentiated 
by abnormalities in cerebrovascular autoregulation, the ability to maintain a stable CBF in 
the face of changing perfusion pressures.
Several preliminary experimental and clinical studies suggested that early administration of 
HmG-Co Reductase Inhibitors (statins) can reduce the incidence of DCI, [2–5] although this 
was not borne out when 40 mg of simvastatin was recently tested in a larger multi-center 
trial. [6] Statins are pleotropic and the mechanisms through which they act in the brain 
remain incompletely understood. It has been proposed that, in addition to their cholesterol 
lowering and anti-inflammatory properties, they act via hemodynamic mechanisms. In 
animal models of stroke, statins raise resting cerebral blood flow (CBF), enhance the 
response to vasodilators and increase endothelial nitric oxide activity, responses that are 
absent in eNOS deficient mice [7, 8] [9]. In experimental subarachnoid hemorrhage (SAH) 
simvastatin administration resulted in augmented eNOS expression.[10] In SAH patients, 40 
mg/d of pravastatin resulted in shorter duration of impaired dynamic autoregulation which 
was assessed using the transient hyperemic responses following carotid artery compression.
[4] However, whether high-dose statin administration can improve CBF after SAH and alter 
static autoregulation has not been evaluated.
Further clarification of the effects of high-dose statins on cerebral autoregulatory function, 
and their relationship to vasospasm and DCI could help refine their use, influence future 
drug development and provide insight into the hemodynamic management of DCI. We chose 
to study statin-naïve patients who were at risk for DCI following acute aneurysmal SAH to 
determine if the initiation of statin therapy induces cerebrovascular hemodynamic effects 
that increase CBF and alter static autoregulatory function during the peak period of risk for 
delayed cerebral ischemia (DCI).
 Methods
 Patient Population
All SAH patients admitted to our institution were screened for eligibility based on the 
following criteria: age > 18 years, SAH from a ruptured cerebral aneurysm, enrolled within 
72 hours of hemorrhage, WNFS ≥2, modified Fisher grade ≥2 on initial CT scan, planned 
surgical or endovascular aneurysm repair, and approval of the attending neurosurgeon. They 
were excluded if they had SAH secondary to traumatic or mycotic aneurysms, had additional 
untreated aneurysms, were receiving pre-ictal statin therapy, had contraindications to statin 
therapy (hypersensitivity; active liver disease or hepatic dysfunction, elevated aspartate 
Diringer et al. Page 2
Neurocrit Care. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
aminotransferase (AST), or alanine aminotransferase (ALT); severe renal dysfunction; 
elevated creatine phosphokinase or had contraindications to induced hypertension (ongoing 
cardiac ischemia, worsening congestive heart failure, aortic dissection, hypertensive 
encephalopathy, malignant hypertension, acute renal failure or were pregnant). Patients were 
randomized by the hospital research pharmacist using a computerized system to in a blinded 
fashion receive either 80 mg of simvastatin or placebo once a day orally or via nasogastric 
tube for 21 days. The protocol was approved by the Human Research Protection Office and 
the Radioactive Drug Research Committee of Washington University. Written consent was 
obtained from patients or their legally authorized surrogate.
Routine care of SAH patients at our institution during the study period consisted of close 
monitoring of fluid balance to maintain a euvolemic state (with isotonic saline administered 
at a rate to maintain daily fluid intake equal or slighter greater than urine output), 
administration of nimodipine 60 mg every 4 hours for 21 days, an anticonvulsant (typically 
levetiracetam 500–1,000 mg twice daily) for 3–7 days following admission, and routine 4-
vessel digital subtraction angiography to assess for vasospasm on day 7–9 following initial 
hemorrhage. A ventriculostomy was performed if hydrocephalus was believed to contribute 
to poor neurological status. DCI was defined as new focal deficit or global decline in 
consciousness after exclusion of other causes of neurological deterioration. If none was 
identified patients were treated with induced hypertension and underwent angiography. In 
the presence of moderate-severe angiographic vasospasm, angioplasty and/or intra-arterial 
infusion of vasodilators were performed. Modified Rankin scale (mRS) was scored in person 
6 months after hemorrhage by a certified research coordinator who was blinded to treatment 
allocation.
 Experimental Procedure
All subjects underwent 15O-PET on post-hemorrhage day 7–10 for measurement of CBF, 
cerebral blood volume (CBV), cerebral metabolic rate for oxygen (CMRO2) and oxygen 
extraction fraction (OEF). Blood pressure (BP) was then raised by 20–25% with infusion of 
phenylephrine or norepinephrine. Once BP was stable for 10 minutes, PET studies were 
repeated. An attending neurointensivist was present in the room at all times. 
Electrocardiography, blood pressure, oxygen saturation, and, when indicated, intracranial 
pressure were continuously monitored and recorded in all patients. Arterial blood gas 
analysis was performed for measurement of partial pressure of CO2 and arterial oxygen 
content (CaO2). At the time of each CBF measurement, clinical and physiological data 
including heart rate, blood pressure, temperature, and arterial blood gas results were 
recorded. Weekly measurements of liver function tests and creatine phosphokinase were 
performed to monitor for statin toxicity.
All patients were studied on the same PET scanner (ECAT Exact HR+ 47; Siemens/CTI, 
Knoxville, TN) located in the neurocritical care unit. A transmission scan was obtained in 
each patient and used for subsequent attenuation correction of emission scan data. The PET 
scans were obtained in the two-dimensional mode. Images were reconstructed with filtered 
back-projection by using measured attenuation and scatter correction to a resolution of 4.3-
mm FWHM. All PET scans were calibrated for conversion of PET counts to quantitative 
Diringer et al. Page 3
Neurocrit Care. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
radiotracer concentrations, as previously described. [11, 12] Radioactivity in arterial blood 
was measured using an automated blood sampler. The arterial time radioactivity curve 
recorded by the sampler was corrected for delay and dispersion by using previously 
determined parameters. CBF was measured by bolus injection of 50–60 mCi 15O-labeled 
water using an adaptation of the Kety autoradiographic method[12–14]. CBV was measured 
after a brief inhalation of 40–50 mCi15O-labeled CO [15]. CMRO2 and OEF were calculated 
using the CBF and CBV measurements and those collected after inhalation of 40–50 
mCi 15O-labeled O2[11, 14].
After completion of the first set of PET measurements, an infusion of phenylephrine or 
norepinephrine was started and the dose increased until the target MAP (20–25% increase 
from blood pressure during the first PET measurements). The MAP was maintained at target 
for a minimum of 10 minutes before PET measurements were repeated. All patients 
underwent diagnostic arteriography, nineteen within 12 hours before or after the PET study.
 Data Processing
For each patient, all emission scans were co-registered and aligned to the initial baseline 
CBV scan using Automated Image Registration software.[16, 17] All images were then co-
registered to a reference brain image and resliced so that data could be localized in Talairach 
atlas space [18]
For each PET scan, a total of 36 spherical regions of 10-mm diameter were placed in the 
anterior, middle and posterior cerebral, basilar and border zone territories bilaterally. [14, 19, 
20] For each patient, we reviewed a computerized tomography scan obtained within 24 
hours of the PET study and compared it with the PET scans. PET regions that corresponded 
to locations within an intracerebral hematoma, retraction edema, or the ventricular system 
were excluded from evaluation. Each patient had a median of 3.2 regions (range 2–9 
regions) excluded from analysis. Regions with low baseline CBF were defined as those with 
CBF <25 ml/100g/min. Cerebrovascular resistance (CVR) was calculated as CVR = MAP/
CBF.
Static autoregulatory index (AI) was calculated as the percentage change in CVR in relation 
to the percentage change in MAP where AI = (%ΔCVR/%ΔMAP) × 100%. Using this 
method AI is expressed as a percentage of full autoregulatory capacity. Thus a change in 
CVR that would fully compensate for the change in MAP (i.e. intact autoregulation) would 
yield an AI of 100%, and no change in CVR would yield a static AI of 0% signifying 
absence of autoregulation. [21]
Angiograms were retrospectively reviewed as previously described.[22] The diameter of 
each large intracranial artery was measured and quantitative percent stenosis was calculated 
relative to baseline angiograms. Distal segments of the ACA, MCA, and PCA were 
qualitatively assigned a vasospasm severity of none, mild, moderate, or severe based on 
visual inspection. Significant vasospasm was considered present if proximal stenosis was at 
least 50% or if severity of distal vasospasm was moderate or severe
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 Data Analysis
Continuous variables are presented as mean and standard deviation, categorical variables as 
median and range. A two-way ANOVA with repeated measures was used to compare CBF in 
the two groups. Categorical variables including proportion of were compared using Fisher’s 
exact test. Since there was no effect of simvastatin, the groups were combined to conduct 
exploratory analyses of the effect of induced hypertension. Two-tailed paired t-tests were 
used to analyze the effect of hypertension on blood pressure, global CBF and oxygen 
delivery. Change in CBF in regions with and without low CBF (<25 ml/100g/min) and 
regions with and without moderate or severe angiographic vasospasm were compared using 
2-tailed unpaired t-tests. To take into account the multiple comparisons performed, a p value 
of < 0.001 was considered statistically significant.
 Results
Thirty-four patients were enrolled; PET studies could not be completed in seven due to 
logistical difficulties (n=4) or patient refusal (n=3). Two of the completed studies could not 
be analyzed for technical reasons. The final PET analyses included 13 patients in the 
simvastatin group and 12 in the placebo group. All had normal HDL and LDL cholesterol 
levels at the time of admission (see Table 1). Presenting characteristics did not differ 
between groups.
All patients were administered oral nimodipine and anticonvulsants on admission; one 
control patient was treated with dexamethasone and 2 patients in each group received 
mannitol. Serum troponin I levels were mildly elevated in 5 control and 7 simvastatin 
patients; none were considered to have had myocardial infarction. External ventricular 
drains were placed in 16 (9 control and 7 simvastatin); 2 patients in each group required 
mechanical ventilation.
 Clinical Endpoints
Clinical DCI developed in 14% of simvastatin patients and 55% of control patients 
(p=0.074). Four control patients were being treated for clinical DCI with vasopressors at the 
time of the PET study. Moderate or severe angiographic vasospasm developed in 42% of the 
simvastatin patients and 45% of controls. Functional outcome on the mRS did not differ 
between groups (Table 1). There were 2 deaths in the simvastatin group (both due to 
decisions to withdraw life-sustaining interventions) and none in the control group.
 PET Data
PET studies were performed 8.6 ± 1.3 days after SAH in the simvastatin group and 8.0 ± 1.8 
days in the control group. Baseline MAP, arterial partial pressure of carbon dioxide (PaCO2), 
arterial oxygen content (CaO2), and other physiologic variables were similar between groups 
at baseline (Table 2). Global baseline CBF, OEF CMRO2, and CVR did not differ between 
groups. MAP was raised 20–25% over a mean of 18 ± 4 minutes and maintained at that level 
at least 10 minutes before repeating PET measurements. PaCO2, CaO2, average global CBF, 
OEF, and CMRO2 did not change when MAP was raised in either group while CVR rose by 
17% in both groups. The average global AI was normal in both groups and they did not 
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differ significantly (95% confidence interval for the difference between means of −39.1 – 
56.3, see Table 2 and Figure 1). When groups were combined global AI did not differ in 
those with or without angiographic vasospasm (92 ± 54% compared with 105 ± 58.8%, 
p=0.59).
On regional analysis 19 regions (5.1%) and in simvastatin patients and 65 regions (15.8%) in 
placebo patients were supplied by vessels with moderate or severe angiographic vasospasm. 
CBF in those regions in simvastatin and placebo patients was 42.8 ± 15.2 vs 38.0 ± 12.3 ml/
100g/min and during hypertension was 37.7 ± 17.0 and 41.3 ± 13.6 ml/100g/min, 
respectively. Contrariwise, there tended to be more regions with low CBF at baseline (<25 
ml/100g/min) in the simvastatin group (11.6% vs. 7.8%, p=0.09) but the mean CBF did not 
change after hypertension (Table 3).
 Safety
Liver function tests and creatine kinase measured on day 7 and 14 did not exceeded 2 
standard deviations above the upper limit of normal except in one patient in the simvastatin 
group. The study drug was discontinued on Day 15 and the values subsequently returned to 
normal. That patient’s data were included in the PET analysis.
 Discussion
In this prospective randomized controlled study of statin- naïve patients following acute 
aneurysmal SAH, we sought to determine if the initiation of therapy with 80 mg of 
simvastatin results in increased CBF and altered autoregulation during the peak period of 
risk for DCI. We found no effect of simvastatin on resting global CBF or static 
autoregulation. While the rates of angiographic vasospasm were similar in both groups, there 
was a trend toward less DCI in those receiving simvastatin; however, this did not result in 
any difference in six-month mRS between groups. These data indicate that despite the 
suggestive findings of pre-clinical studies, high-dose simvastatin does not improve resting 
CBF or change autoregulation in SAH patients at high-risk for DCI.
The only prior study to assess the impact of statins on autoregulation after SAH was 
performed by Tseng et al.[23] They utilized the transcranial Doppler transient hyperemic 
response test (THRT) to temporary carotid occlusion to assess dynamic autoregulation in 
SAH patients randomized to 40 mg of pravastatin or placebo. A daily THRT was performed 
and the duration of impaired autoregulation was found to be shorter in the pravastatin group. 
No data were provided regarding the incidence of abnormal autoregulation or the degree of 
impairment. In contrast, we assessed autoregulation at only one time point using a static 
rather than dynamic methodology.
Recently two large prospective randomized controlled trials were completed addressing the 
clinical utility of statins in SAH. The STASH trial compared 40 mg of simvastatin to 
placebo in 803 SAH patients[24]. The primary ordinal analysis of the mRS, adjusted for age 
and WFNS grade on admission, showed no benefit. In another study Wong et al. compared 
low and high dose simvastatin, 40 vs. 80 mg. [25] The groups did not differ in the incidence 
of delayed ischemic deficits (27% versus 24%) or in the rate of favorable outcomes (mRS 
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score 0–2) at 3 months (73% versus 72%). Taken together these data indicate that 
simvastatin likely does not improve functional outcome in SAH. Still, it has been suggested 
that the failure to detect a benefit may be due to the insensitivity of the mRS to cognitive 
outcome or that a subset of patients might respond. [26]
This study also provides insight into the physiologic response to induced hypertension and 
capacity for autoregulation in SAH patients. Since the 1970s a number studies assessed 
vascular reactivity in SAH patients reporting a diversity of findings including: preserved 
static autoregulation in the absence of intracerebral haemorrhage, hydrocephalus or 
vasospasm,[27] altered static autoregulation and CO2 reactivity during early surgery, [28] 
impaired vasodilation during hypotension, [28, 29] correlation between impaired 
autoregulation and severe neurological deficits, severe angiographic vasospasm and marked 
depression of global CBF. [30] In a recent review Budohoski noted that the nature of 
autoregulatory failure varied considerably across studies and argued that such variability in 
outcomes suggests that autoregulatory failure is heterogeneous and depends on the 
prevailing pathophysiological mechanism.[31] Of note all of these studies assessed 
autoregulation by lowering blood pressure, thus assessing vasodilatory capacity. How these 
finding relate to testing autoregulation by raising blood pressure, which assesses 
vasoconstrictive function, is unknown.
More recently, numerous studies have reported abnormal dynamic autoregulation in SAH 
patients.[32–36] This approach differs from static autoregulation in that it either requires a 
physiologic maneuver to induce a transient blood pressure stimulus (leg or carotid 
compression) or more typically relies on spontaneous fluctuations of blood pressure. In 
addition, unlike static autoregulatory testing which provides a snapshot, it allows for 
continuous assessment over days. About three-quarters of studies that assessed dynamic 
autoregulation reported autoregulatory dysfunction as a result of SAH, and disturbed 
autoregulation was consistently associated with DCI and poor outcome. Interpretation of 
results using these methods, however, is complicated by the heterogeneity of the monitored 
parameter, physical locations of the sensors and lack of a standardized method for 
calculation of dynamic autoregulation.[31, 37]
In 1976 Kosnik and Hunt proposed to capitalize on impaired autoregulation in SAH by 
elevating blood pressure to reverse neurologic symptoms.[38] Their thesis was that 
“autoregulation is poor or absent in these patients, and that cerebral blood flow therefore 
follows the mean arterial pressure.” Over time induced hypertension evolved to be the 
mainstay of medical therapy to treat DCI.[39] Very few studies, however, have directly 
assessed the CBF response to induced hypertension. Darby et al. measured regional CBF 
using Xenon-CT in 13 patients with DCI before and after raising mean blood pressure from 
90 to 111 mm Hg with dopamine. [40] Global CBF did not change. CBF rose to above 
ischemic levels in two-thirds of the regions with low baseline CBF but fell in other regions 
raising concerns about cerebral vasoconstriction from dopamine. In a retrospective review of 
clinical data, another group reported on five patients with severe angiographic vasospasm 
treated with phenylephrine to increase MAP from 102.4 to 132.1 mm Hg. They reported that 
in regions of diminished CBF, mean CBF increased from 19.2 to 33.7 ml/100 g/min.[41] No 
additional details are provided about global CBF, how regions were selected, or what 
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occurred to CBF in other regions. A recent study reported on 25 SAH patients randomized 
to induced hypertension or control and used CT perfusion to measure the change in CBF. 
They found that raising BP an average of 12 mm Hg did not change global or CBF or CBF 
asymmetry in the region with the lowest baseline flow.[42]
Several points must be considered when interpreting these data. First, the autoregulatory 
response acts through both vasodilation and vasoconstriction. In SAH patients, testing both 
arms of the response in a single patient is logistically extremely difficult and has not been 
reported. The majority of static autoregulation studies tested the response to lowering 
pressure whereas only a handful of SAH patients have been reported testing the response to 
elevating pressure.
Second, autoregulation is a complex response whereby, under normal and stable conditions, 
CVR changes in response to changes in perfusion pressure to maintain stable oxygen 
delivery. Thus the definition of autoregulation assumes normal and stable physiological 
conditions such that oxygen demand and delivery are well matched. In disease states, 
however, several parameters may be disturbed. During ischemia, then cerebral vessels have 
already been subject to strong signals to dilate and thus unable to compensate for a fall in 
perfusion. While some may refer to this as impaired autoregulation, in fact the vasculature is 
responding appropriately but unable to dilate enough to response to the conditions. Third, 
despite our attempt to enrol patients a high risk of DCI the outcome is both groups was quite 
good. How these findings apply to more severely affected patients in uncertain.
In summary, our data indicate that initiation of therapy with high dose simvastatin does not 
alter average baseline CBF or induced hypertension.
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Figure 1. 
Each point represents an individual patient. Global autoregulatory index was calculated as 
AI = (%ΔCVR/%ΔMAP) × 100%. A change in CVR that would fully compensate for the 
change in MAP would yield an AI of 100%, and no change in CVR would yield a static an 
AI of 0%. Horizontal bar indicated group mean.
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Table 1
Patient characteristics
Simvastatin Placebo
N 13 12
Age 59 ± 12 60 ± 10
Gender – Female % 62% 67%
Race – Caucasian % 86% 92%
Smoker (%) 38% 50%
Hypertension (%) 23% 50%
Coronary artery disease (%) 0 8%
*HDL cholesterol (mean ± SD) 57 ± 18.3 63 ± 19.8
*LDL cholesterol (mean ± SD) 115 ± 51.9 81 ± 26.8
*Anti-platelet therapy (%) 0 8%
Heavy alcohol use (%) 7% 8%
Admitted on SAH day (%)
Day of hemorrhage – 10 Day of hemorrhage – 9
1 day post bleed - 3 1 day post bleed - 2
2 days post bleed - 1
*
 Mean blood pressure (mean ± SD) 107 ± 11.9 102 ± 23.2
Intubated (%) 7% 16%
*WFNS Grade(N)
2 – 4 2 – 2
3 – 6 3 – 3
4 – 1 4 – 5
5 – 2 5 – 2
*Modified Fisher Scale (N)
1 – 0 1 – 1
2 – 2 2 – 2
3 – 7 3 – 6
4 – 4 4 – 3
*Intraventricular hemorrhage(%) 46% 67%
Moderate/severe angiographic vasospasm (%) 42% 45%
Delayed cerebral ischemia with rescue therapy (%) 14% 55%
Modified Rankin Scale (6-month) N N
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Simvastatin Placebo
 0 3 0
 1 3 2
 2 4 4
 3 0 4
 4 0 2
 5 1 0
 6 2 0
*On admission
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